上皮膜蛋白-2(EMP2)促进多形性胶质母细胞瘤血管生成
研究利用人胶质母细胞瘤(GBM)细胞系,在体外和体内证实肿瘤表达的上皮膜蛋白-2(EMP2)促进血管生成,部分通过上调肿瘤血管内皮生长因子A(VEGF-A)水平实现。全身给予抗EMP2 IgG1可观察到颅内异种移植瘤负荷显著减少、肿瘤血管减少,提示其作为GBM新型抗血管生成治疗的潜力,但需进一步研究。
要点
- EMP2在体外和体内均促进GBM血管生成,部分通过上调肿瘤VEGF-A水平实现。
- 全身给予抗EMP2 IgG1可显著减少颅内异种移植瘤负荷并减少肿瘤血管。
- 抗EMP2 IgG1可能成为GBM新型抗血管生成治疗,但需进一步研究分子机制并进一步表征。
核心结论
- 肿瘤表达EMP2在体外和体内促进GBM血管生成,部分通过上调肿瘤VEGF-A水平实现。
- 全身给予抗EMP2 IgG1可观察到颅内异种移植瘤负荷显著减少和肿瘤血管减少,提示其作为GBM新型抗血管生成治疗的潜力。
- 需进一步研究以充分理解EMP2调控GBM发病和进展的分子机制,并进一步表征抗EMP2治疗在GBM中的作用。
研究设计与样本
- 研究使用人GBM细胞系,在体外和体内评估EMP2对血管生成的作用,并观察全身给予抗EMP2 IgG1对颅内异种移植瘤的潜在治疗效果。
主要发现
- EMP2在体外和体内均促进血管生成,该促血管生成效应部分通过上调肿瘤VEGF-A水平实现。
- 全身给予抗EMP2 IgG1后,颅内异种移植瘤负荷显著减少,肿瘤血管减少。
- 贝伐珠单抗(抗VEGF-A单克隆抗体)提示无进展生存获益但无总生存获益。
临床怎么用
- 作者认为抗EMP2 IgG1可能成为GBM有前景的新型抗血管生成治疗。
- 原文未据此给出临床推荐。
局限性
- 需进一步研究以充分理解EMP2调控GBM发病和进展的分子机制,并进一步表征抗EMP2治疗在GBM中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor and is associated with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling GBM growth. In this study, we demonstrate tumor expression of epithelial membrane protein-2 (EMP2) promotes angiogenesis both in vitro and in vivo using cell lines from human GBM. Mechanistically, this pro-angiogenic effect of EMP2 was partially through upregulating tumor VEGF-A levels. A potential therapeutic effect of a systemic administration of anti-EMP2 IgG1 on intracranial xenografts was observed resulting in both significant reduction of tumor load and decreased tumor vasculature. These results suggest the potential for anti-EMP2 IgG1 as a promising novel anti-angiogenic therapy for GBM. Further investigation is needed to fully understand the molecular mechanisms how EMP2 modulates GBM pathogenesis and progression and to further characterize anti-EMP2 therapy in GBM.
引用
- Qin Y, Takahashi M, Sheets K, et al. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017. PMID: 28597184. doi:10.1007/s11060-017-2507-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。